<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01496352</url>
  </required_header>
  <id_info>
    <org_study_id>DFA-02-CD-002</org_study_id>
    <nct_id>NCT01496352</nct_id>
  </id_info>
  <brief_title>DFA-02 in Patients Undergoing Colorectal Surgery</brief_title>
  <official_title>A Randomized, Double-blind, Placebo Controlled, Safety, Tolerability, and Pharmacokinetic Dose Escalation Study of DFA-02 in Patients Undergoing Colorectal Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Reddy's Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Duke Clinical Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Dr. Reddy's Laboratories Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, placebo controlled, safety, tolerability, and
      pharmacokinetic dose escalation Phase II study of DFA-02 in patients undergoing colorectal
      surgery to evaluate the safety, tolerability and pharmacokinetics of DFA-02.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Despite antibiotic prophylaxis and improvements in surgical techniques, surgical site
      infections (SSI) still occur. DFA-02 is a novel bioresorbable modified release gel containing
      both gentamicin and vancomycin to be applied during surgical incision closure for the
      prevention of surgical site infections (SSIs) in patients undergoing colorectal surgery.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients With Adverse Events, Laboratory, Physical Examination Changes</measure>
    <time_frame>Baseline up to Day 30</time_frame>
    <description>Safety and tolerability measured by number of patients with adverse events or changes in laboratory or physical examination findings from baseline (DFA-02 application during surgery on Day 1) to 30 days after surgery.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under Curve (AUC)</measure>
    <time_frame>1, 6, 24, 48 96 hours post-dose</time_frame>
    <description>Area under the curve (AUC) of plasma gentamicin and vancomycin levels using sparse sampling from baseline (DFA-02 application during surgery on Day 1) to 4 days after surgery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximal Plasma Concentration (Cmax)</measure>
    <time_frame>1, 6, 24, 48, 96 hours post-dose</time_frame>
    <description>Maximal plasma concentration (Cmax)of gentamicin and vancomycin using sparse sampling from baseline (DFA-02 application during surgery on Day 1) to 4 days after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal Function</measure>
    <time_frame>Baseline up to Day 14</time_frame>
    <description>Changes in serum creatinine from surgery on Day 1 until 14 days after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibiotic Resistance</measure>
    <time_frame>Baseline up to Day 5</time_frame>
    <description>Methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococcus presence at surgery on Day 1 and 5 days after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Surgical Site Infection</measure>
    <time_frame>Up to 30 Days After Surgery</time_frame>
    <description>The incidence of probable or definite surgical site infection as determined by the Investigator.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Surgical Site Infection</condition>
  <arm_group>
    <arm_group_label>DFA-02</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Progressive cohorts of 10 subjects (8 active, 2 placebo) receiving 10, 20 , 30 or 40 mL of DFA-02 or matching placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DFA-02 placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DFA-02</intervention_name>
    <description>Modified release product containing gentamicin and vancomycin for application at the conclusion of surgery after closure of the fascia and prior to skin closure</description>
    <arm_group_label>DFA-02</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>DFA-02 placebo</description>
    <arm_group_label>DFA-02 placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males and females 18 years of age or older;

          2. If female, the patient must be:

               -  postmenopausal (if amenorrheic for &lt; 1 year, postmenopausal status must be
                  confirmed by an elevated follicle stimulating hormone [FSH] level &gt; 30 mIU/mL; if
                  amenorrheic for &gt; 1 year, FSH level not required);

               -  surgically sterilized (does not have a uterus or has had bilateral tubal
                  ligation); or

               -  if of child-bearing potential, she must have a negative serum pregnancy test on
                  entry in the study, and agree to use adequate birth control during the study and
                  for 30 days after the administration of study agent. Medically acceptable
                  contraceptives include: (1) surgical sterilization (such as a tubal ligation or
                  hysterectomy), (2) approved hormonal contraceptives (such as birth control pills,
                  patches, implants or injections), (3) barrier methods (such as a condom or
                  diaphragm) used with a spermicide, or (4) an intrauterine device (IUD);

          3. BMI 25-40, inclusive;

          4. Scheduled to undergo nonemergent colorectal surgery involving a laparotomy incision of
             7 cm or greater (hand-assisted laparoscopic surgery is allowed). List of eligible
             procedures: left, right or transverse colectomy, segmental/sleeve left colon
             resection, total abdominal colectomy with ileorectal anastomosis, total abdominal
             colectomy with ileostomy, total abdominal proctocolectomy, low anterior resection,
             sigmoid resection, non-emergent Hartmann's procedure, colotomy with polypectomy distal
             to hepatic flexure, colostomy takedown through laparotomy (not peristomal) incision,
             ileo-pouch anal anastomosis, abdominal perineal resection of the rectum;

          5. Willing and able to give informed consent;

          6. Available for evaluation from baseline until final evaluation at 30 days post surgery.

        Exclusion Criteria:

          1. Known history of hypersensitivity to gentamicin or vancomycin, other aminoglycoside
             antibiotics or the excipients of the study products (soy bean products or sesame oil);

          2. Emergency surgery (urgent surgery is allowed if informed consent is obtained and the
             study procedures can be performed);

          3. Significant concomitant surgical procedure (Note: concomitant appendectomy,
             cholecystectomy, oophorectomy, and liver biopsy/wedge resection are allowed);

          4. Prior laparotomy within the last 60 days of this planned procedure;

          5. Planned second laparotomy or colorectal surgical procedure (e.g. colostomy or
             ileostomy takedown) within 30 days of this planned first procedure;

          6. Expectation that a surgical drain will be placed;

          7. Preoperative sepsis, severe sepsis, or septic shock;

          8. Abdominal wall infection/surgical site infection from previous laparotomy/laparoscopy
             or for any reason;

          9. Active systemic infection or systemic (oral or intravenous) antibiotic therapy within
             the 1 week prior to the date of surgery other than specified preoperative
             antimicrobial prophylaxis (Note: single dose antibiotic therapy for dental or other
             minor procedures is allowed as is the use of oral non-absorbable antibiotics for
             preoperative bowel decontamination);

         10. Requirement for gentamicin or vancomycin preoperative antimicrobial prophylaxis (Note:
             systemic antibiotic therapy within 72 hours after surgery with gentamicin or
             vancomycin must be avoided and any systemic antibiotic therapy during that time should
             be discussed with the Coordinating Center PI or Medical Monitor);

         11. Requirement for concomitant use or use during the 30 days prior to Day 1 of any
             prescription or OTC drug that would interfere with the study or place the patient at
             undue risk. Concurrent systemic or topical use of other potentially neurotoxic,
             nephrotoxic, and/or ototoxic drugs, such as gentamicin, cisplatin, cephaloridine,
             kanamycin, amikacin, polymyxin B, colistin, paromomycin, streptomycin, tobramycin,
             vancomycin, ethacrynic acid, furosemide, and viomycin, should be avoided;

         12. Preoperative evaluation suggests an intra-abdominal process that might preclude full
             closure of the skin;

         13. Ongoing treatment (e.g. chemotherapy, radiation) for non-colorectal cancer;

         14. History of significant drug or alcohol abuse within the past year;

         15. Serum Creatinine &gt; 1.3 mg/dL

         16. Serum Bilirubin &gt; 2.5 times upper limit of normal;

         17. History of uncontrolled diabetes mellitus (controlled diabetic patients whose
             hemoglobin A1c is â‰¤ 9.0% may be included);

         18. Patients who are immunocompromised including but not limited to systemic
             corticosteroid use or chemotherapy/radiation during the 30 days prior to surgery,
             organ transplantation, or HIV infection (Note: inhaled corticosteroids are not
             exclusionary and single dose use of corticosteroids to prevent PONV is allowed.);

         19. Any clinically meaningful hearing loss (from Medical History);

         20. Clinically exclusionary results on clinical laboratory, ECG, or physical examination
             including but not limited to positive hepatitis B or C or HIV;

         21. Pregnant or lactating, or if of childbearing potential not practicing a birth control
             method with a high degree of reliability;

         22. Refusal to accept medically indicated blood products;

         23. Participation within 30 days before the start of this study in any experimental drug
             or device study, or currently participating in a study in which the administration of
             investigational drug or device within 60 days is anticipated;

         24. Patients with anterior abdominal wall mesh that is not planned to be completely
             removed during the planned procedure;

         25. Unable to participate in the study for any reason in the opinion of the Principal
             Investigator;

         26. Postsurgical life expectancy of less than 30 days, in the Investigator's or Sponsor's
             opinion;

         27. Expected discharge from the hospital less than 3 days after surgery.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kent Allenby, MD</last_name>
    <role>Study Director</role>
    <affiliation>Dr. Reddy's Laboratories</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Florence</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bellaire</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 15, 2011</study_first_submitted>
  <study_first_submitted_qc>December 19, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 21, 2011</study_first_posted>
  <results_first_submitted>August 15, 2014</results_first_submitted>
  <results_first_submitted_qc>August 15, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 1, 2014</results_first_posted>
  <last_update_submitted>August 15, 2014</last_update_submitted>
  <last_update_submitted_qc>August 15, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 1, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Surgical site infection</keyword>
  <keyword>Colorectal surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Surgical Wound Infection</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study Period: February 12, 2012 to June 27, 2013. Patients were enrolled at four hospital based sites in the US (Tampa, FL; Temple, Tx; Florence, AL; Houston, TX).</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>DFA-02</title>
          <description>Progressive cohorts of 8 subjects per cohort receiving up to 10, 20 or 30 mL of DFA-02
DFA-02: Modified release product containing gentamicin and vancomycin for application at the conclusion of surgery after closure of the fascia and prior to skin closure</description>
        </group>
        <group group_id="P2">
          <title>DFA-02 Placebo</title>
          <description>Progressive cohorts of 2 patients per cohort receiving up to 10, 20 or 30 mL of DFA-02 placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>DFA-02</title>
          <description>Progressive cohorts of 8 subjects per cohort receiving up to 10, 20 or 30 mL of DFA-02</description>
        </group>
        <group group_id="B2">
          <title>DFA-02 Placebo</title>
          <description>Progressive cohorts of 2 subjects per cohort receiving up to 10, 20 or 30 mL of DFA-02 placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.8" spread="14.91"/>
                    <measurement group_id="B2" value="58.5" spread="16.7"/>
                    <measurement group_id="B3" value="62.0" spread="15.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black/African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.8" spread="4.00"/>
                    <measurement group_id="B2" value="27.8" spread="2.47"/>
                    <measurement group_id="B3" value="29.4" spread="3.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Adverse Events, Laboratory, Physical Examination Changes</title>
        <description>Safety and tolerability measured by number of patients with adverse events or changes in laboratory or physical examination findings from baseline (DFA-02 application during surgery on Day 1) to 30 days after surgery.</description>
        <time_frame>Baseline up to Day 30</time_frame>
        <population>As Treated</population>
        <group_list>
          <group group_id="O1">
            <title>DFA-02</title>
            <description>Progressive cohorts of 8 subjects receiving up to 10, 20 or 30 mL of DFA-02</description>
          </group>
          <group group_id="O2">
            <title>DFA-02 Placebo</title>
            <description>Progressive cohorts of 2 subjects receiving 10, 20 or 30 mL of DFA-02 placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Adverse Events, Laboratory, Physical Examination Changes</title>
          <description>Safety and tolerability measured by number of patients with adverse events or changes in laboratory or physical examination findings from baseline (DFA-02 application during surgery on Day 1) to 30 days after surgery.</description>
          <population>As Treated</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Adverse Event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Serious Adverse Event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Adverse Event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under Curve (AUC)</title>
        <description>Area under the curve (AUC) of plasma gentamicin and vancomycin levels using sparse sampling from baseline (DFA-02 application during surgery on Day 1) to 4 days after surgery</description>
        <time_frame>1, 6, 24, 48 96 hours post-dose</time_frame>
        <population>All Subjects Receiving Active Drug</population>
        <group_list>
          <group group_id="O1">
            <title>DFA-02</title>
            <description>Progressive cohorts of 8 subjects per cohort receiving up to 10, 20 or 30 mL of DFA-02</description>
          </group>
          <group group_id="O2">
            <title>DFA-02 Placebo</title>
            <description>Progressive cohorts of 2 subjects per cohort receiving up to 10, 20 or 30 mL of DFA-02 placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under Curve (AUC)</title>
          <description>Area under the curve (AUC) of plasma gentamicin and vancomycin levels using sparse sampling from baseline (DFA-02 application during surgery on Day 1) to 4 days after surgery</description>
          <population>All Subjects Receiving Active Drug</population>
          <units>mcg/h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Gentamicin AUC (0-t)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.2" spread="12.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vancomycin AUC (0-t)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.47" spread="8.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximal Plasma Concentration (Cmax)</title>
        <description>Maximal plasma concentration (Cmax)of gentamicin and vancomycin using sparse sampling from baseline (DFA-02 application during surgery on Day 1) to 4 days after surgery</description>
        <time_frame>1, 6, 24, 48, 96 hours post-dose</time_frame>
        <population>All subjects receiving DFA-02 active gel</population>
        <group_list>
          <group group_id="O1">
            <title>DFA-02</title>
            <description>Progressive cohorts of 18 subjects receiving up to 10, 20 or 30 mL of DFA-02</description>
          </group>
          <group group_id="O2">
            <title>DFA-02 Placebo</title>
            <description>Progressive cohorts of 2 subjects per cohort receiving up to 10, 20 and 30 mL of DFA-02 placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Maximal Plasma Concentration (Cmax)</title>
          <description>Maximal plasma concentration (Cmax)of gentamicin and vancomycin using sparse sampling from baseline (DFA-02 application during surgery on Day 1) to 4 days after surgery</description>
          <population>All subjects receiving DFA-02 active gel</population>
          <units>mcg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Gentamicin Cmax</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.642" spread="0.524"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vancomycin Cmax</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.164" spread="0.150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Renal Function</title>
        <description>Changes in serum creatinine from surgery on Day 1 until 14 days after surgery</description>
        <time_frame>Baseline up to Day 14</time_frame>
        <population>As treated</population>
        <group_list>
          <group group_id="O1">
            <title>DFA-02</title>
            <description>Progressive cohorts of 8 subjects per cohort receiving up to 10, 20 or 30 mL DFA-02</description>
          </group>
          <group group_id="O2">
            <title>DFA-02 Placebo</title>
            <description>Progressive cohorts of 2 subjects per cohort receiving 10, 20 or 30 mL DFA-02 placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Renal Function</title>
          <description>Changes in serum creatinine from surgery on Day 1 until 14 days after surgery</description>
          <population>As treated</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Moderate Elevated Serum Creatinine Day 5 or Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe/LifeThreatening Elevated Serum Creatinine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Antibiotic Resistance</title>
        <description>Methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococcus presence at surgery on Day 1 and 5 days after surgery</description>
        <time_frame>Baseline up to Day 5</time_frame>
        <population>As Treated</population>
        <group_list>
          <group group_id="O1">
            <title>DFA-02</title>
            <description>Progressive cohorts of 8 subjects per cohort receiving up to 10, 20 or 30 mL DFA-02</description>
          </group>
          <group group_id="O2">
            <title>DFA-02 Placebo</title>
            <description>Progressive cohorts of 2 subject per cohort receiving up to 10, 20 or 30 mL DFA-02 placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Antibiotic Resistance</title>
          <description>Methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococcus presence at surgery on Day 1 and 5 days after surgery</description>
          <population>As Treated</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Nasal MRSA Conversion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rectal Vancomycin Resistant Enterococcus Conversio</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Surgical Site Infection</title>
        <description>The incidence of probable or definite surgical site infection as determined by the Investigator.</description>
        <time_frame>Up to 30 Days After Surgery</time_frame>
        <population>As treated</population>
        <group_list>
          <group group_id="O1">
            <title>DFA-02</title>
            <description>Progressive cohorts of 8 subjects receiving up to 10, 20 or 30 mL DFA-02</description>
          </group>
          <group group_id="O2">
            <title>DFA-02 Placebo</title>
            <description>Progressive cohorts of 2 subjects per cohort receiving up to 10, 20 or 30 mL DFA-02 placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Surgical Site Infection</title>
          <description>The incidence of probable or definite surgical site infection as determined by the Investigator.</description>
          <population>As treated</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From Informed Consent to 30 Days After Surgery</time_frame>
      <group_list>
        <group group_id="E1">
          <title>DFA-02</title>
          <description>Progressive cohorts of 8 subjects per cohort receiving up to 10, 20 or 30 mL of DFA-02</description>
        </group>
        <group group_id="E2">
          <title>DFA-02 Placebo</title>
          <description>Progressive cohorts of 2 subjects per cohort receiving up to 10, 20 or 30 mL of DFA-02 placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>Verbatim</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bowel Obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Anastomotic Leak</sub_title>
                <description>Small Bowel Anastomotic Leak with Secondary Sepsis</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Surgical Site Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Post-operative Bleeding</sub_title>
                <description>Mesenteric Vessel Bleeding</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Anastomotic Dehiscence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <description>Anastomotic leak followed by venous thrombosis followed by death</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood and Lymphatic System Disorders</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="24"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Disorders</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="24"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal Disorders</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="24"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General Disorders and Administration Site Conditions</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatobiliary Disorders</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections and Infestations</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury, Poisoning and Procedural Complications</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="24"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Investigations</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="24"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Metabolism and Nutritional Disorders</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="24"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal and Connective Tissue Disorders</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Nervous System Disorders</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychiatric Disorders</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal and Urinary Disorders</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory, Thoracic and Mediastinal Disorders</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin and Subcutaneous Disorders</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vascular Disorders</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="24"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Protocol specified cohorts of 10, 20, 30 or 40 mL to be placed after closure of the fascia and prior to skin closure. Experience with 20 and 30 mL dose levels showed that even largest patients would not accommodate 40 mL so that arm was not done.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Kent Allenby, MD, VP, Drug Development</name_or_title>
      <organization>Dr. Reddy's Laboratories, Inc.</organization>
      <phone>609-375-9855</phone>
      <email>kallenby@drreddys.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

